Synchron Stock

synchron.comHealthcare / Medical DevicesFounded: 2016Funding to Date: $118.41MM

Synchron has developed an endovascular brain computer interface that can access every corner of the brain using its natural highways, the blood vessels. Their breakthrough platform launches a new frontier for the treatment of neurological diseases: Neurointerventional Electrophysiology (Neuro EP). This company was founded in 2016 and is headquartered in Brooklyn, NY.

Register for Details

For more details on financing and valuation for Synchron, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Synchron.

Register Today


Management Team

Thomas Oxley Ph.D
Co-Founder, Chief Executive Officer & Board Member
Nicholas Opie Ph.D
Co-Founder, Chief Technology Officer & Board Member
Amos Meltzer
Chief Legal Officer
Rahul Sharma
Co-Founder & Board Member
J Mocco
Chief Medical Officer
Kurt Haggstrom
Chief Commercial Officer
Connie Rey
Vice President, Clinical Affairs
Gary Castro
Vice President, Finance
Riki Banerjee
Vice President, Research & Development

Board Members

Alexander Morgan Ph.D
Khosla Ventures
Ari Nowacek Ph.D
ARCH Venture Partners
Martin Dieck
NeuroTechnology Investors
Robert Nelsen
ARCH Venture Partners
Josh Duyan
Artisan Partners

Other companies like Synchron in the Medical Devices sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Synchron to start patient enrolment in brain-computer interface study
Synchron, an endovascular brain-computer interface (BCI) firm, has begun patient enrolment for its COMMAND study. The study will assess the safety and efficacy of the Synchron Switch, a BCI device that helps people with limited mobility operate technology using their thoughts. The device is implanted using a minimally-invasive procedure and the study will evaluate its impact on daily tasks such as texting, emailing, and online shopping.
Tom Oxley: translating thoughts into text with brain implants
Tom Oxley, a physician and entrepreneur, is developing an implantable brain-computer interface at his company, Synchron. The technology allows a patient's thoughts to be transmitted wirelessly through the skin to control digital devices. Oxley is a neurointerventionist at Mount Sinai Hospital and has performed over 1,600 endovascular neurosurgical procedures.
The race to beat Elon Musk to put chips in people's brains
Paradromics Inc. is developing an electronic brain implant that allows the mind to communicate directly with a computer, aiming to restore the voice of people who have lost the ability to speak or type. The company has attracted investors who believe it can beat Elon Musk's Neuralink to market. Since Musk launched Neuralink in 2017, Paradromics and three other leading companies have raised over $240 million. The technology faces regulatory hurdles and ethical questions, but could potentially offer a cognitive advantage to healthy people who receive an implant.
Updated on: Sep 23, 2023